F2G

F2G is a clinical-stage biopharmaceutical company focused on the discovery & development of novel therapies to treat life-threatening invasive fungal infection.

[F2G @F2Gltd]

We’re pleased to announce the topline data from our Phase 3 study conducted in collaboration with Shionogi & Co. in patients with invasive fungal disease. Visit our website to view our press release: https://t.co/WtyQQ6SbI4
FOR INVESTORS & JOURNALISTS ONLY

[F2G @F2Gltd]

This National Safety Month, we're raising awareness about #ValleyFever, a fungal disease linked to inhaling airborne spores from disturbed soil. Prevention starts with awareness. Learn more: https://t.co/4XJOYiOOZE
#NSM

[F2G @F2Gltd]

Could The Last of Us become more than fiction? Fungal pathogens are evolving & becoming harder to treat. At #BIO2026 we are discussing growing challenges of fungal disease & the need to stay ahead of new threats.
📅 June 22 | 🕒 3:00 PM–4:00 PM
Learn more: https://t.co/8n6youNVy1

[F2G @F2Gltd]

Our CEO, Francesco Maria Lavino, will join a #BIO2026 panel exploring how innovation, policy and partnerships can help address challenges in infectious diseases. The session brings together cross sector perspectives shaping the field.

Learn more: https://t.co/8n6youNVy1

[F2G @F2Gltd]

During #OlderAmericansMonth, the theme #ChampionYourHealth highlights prevention and informed care. As people age, infections like invasive aspergillosis can pose greater risks, especially for those with weakened immune systems. Learn more: https://t.co/2LjPqqTJAE

[F2G @F2Gltd]

At #ESCMIDGlobal2026, we engaged with the infectious disease community on ongoing challenges in fungal diseases and explored potential solutions. Conversations like these underscores the importance of collaboration for innovation. Learn about our progress: https://t.co/8dazZe07Wp

[F2G @F2Gltd]

Our team is attending @ESCMID Global 2026 and looks forward to engaging with the #InfectiousDisease community in knowledge exchange around innovative solutions to address fungal infections.

Learn more here: https://t.co/Ucaa1tNMg4
#ESCMIDGlobal2026

[F2G @F2Gltd]

#WorldHeathDay spotlights the importance of One Health approach that protects human, animal, and environmental health. We believe it is critical to addressing antifungal resistance. Learn more: https://t.co/nuBTSKaV5n

[F2G @F2Gltd]

F2G was proud to sponsor the Valley Fever Walk, raising awareness of #ValleyFever. We remain committed to advancing innovative antifungal therapies that bring hope to patients and supporting the Institute's efforts to STRIKE OUT 💥⚾ Valley Fever.

[F2G @F2Gltd]

Antimicrobial resistance is often discussed through bacteria, but fungal pathogens present a distinct challenge. Our CMO, John Rex, MD, shares why antifungal drug development is uniquely difficult & why innovation is urgently needed. Read more: https://t.co/uobyPzr5ea

[F2G @F2Gltd]

Invasive aspergillosis is a serious #FungalInfection caused by #Aspergillus that may be life-threatening in immunocompromised patients. Learn more about the fungal disease and our progress towards addressing it: https://t.co/6F7nyPFnds

[F2G @F2Gltd]

We’re pleased to share that our awareness initiative with @LifeSciComms on the threat of fungal infections earned a @PRDaily Award. As The Last of Us broadened public attention, we used the moment to reach wider audiences and educate around this urgent issue.

[F2G @F2Gltd]

We’re proud to have received the award for Late Venture Round / Series C+ Raise of the Year at the 2025 European #LifestarsAwards. We’re grateful to our team and investors for their dedication and support as we continue advancing novel treatments for invasive fungal infections.

[F2G @F2Gltd]

We’re excited to present four posters at @TIMM_cc, demonstrating our commitment to advancing novel treatments for invasive fungal infections. We look forward to connecting with peers in the #InfectiousDisease space from September 19-22 in Bilbao, Spain!

#TIMM2025

[F2G @F2Gltd]

Antimicrobial-resistant fungal infections are on the rise worldwide, creating new challenges for treatment. At F2G, we are increasing awareness of the threat of cross-resistance and advancing efforts to address it. Learn from the @CDCgov this #FungalWeek25:https://t.co/8SDXbpmaw4

[F2G @F2Gltd]

Fungal diseases can move between people, animals, and the environment. Climate change and ecosystem shifts are increasing their reach. One Health helps us understand these connections and take action. Learn more from the @CDCgov this #FungalWeek25: https://t.co/nuBTSKaV5n

[F2G @F2Gltd]

We’re pleased to announce the publication of our Phase 2b data on our novel antifungal drug candidate in @TheLancetInfDis. Visit our website to view our press release: https://t.co/8dazZe07Wp

FOR INVESTORS & JOURNALISTS ONLY

[F2G @F2Gltd]

We’re proud to share that F2G has relocated its UK operations to @AlderleyPark, a leading UK science & innovation campus. We were honored to welcome Prof. Sir Chris Whitty, the UK’s CMO, to discuss the urgent need for antifungal innovation. Learn more: https://t.co/hXfjLB7EdA

[F2G @F2Gltd]

Our VP of Market Access, Jonathan Bruce, will speak at the @OrphanConf on April 24, joining a panel focused on evolving policy landscapes and access to care in rare disease. The session will take place at 2:20pm ET in Theater 4, Room 050. Full agenda here: https://t.co/vH6OZxTzxh

[F2G @F2Gltd]

We’re proud to sponsor the 69th Annual Coccidioidomycosis Study Group, taking place April 4-5, 2025. At F2G, we’re committed to advancing the understanding and treatment of serious fungal infections through knowledge sharing and innovation. Learn more: https://t.co/I43DgO9s1e